Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-27 @ 10:54 PM
Study NCT ID:
NCT01331694
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2011-03-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-07
Start Date Type:
None
Primary Completion Date:
2010-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-05
Completion Date Type:
ACTUAL
First Submit Date:
2011-03-10
First Submit QC Date:
None
Study First Post Date:
2011-04-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-03-10
Results First Submit QC Date:
None
Results First Post Date:
2011-04-08
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-06-02
Last Update Post Date:
2017-07-02
Last Update Post Date Type:
ACTUAL